Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 14, 2019

SELL
$15.53 - $19.75 $2.58 Million - $3.28 Million
-166,068 Closed
0 $0
Q2 2018

Aug 13, 2018

BUY
$27.78 - $38.53 $4.61 Million - $6.4 Million
166,068 New
166,068 $4.7 Million

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $88.3M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Axa S.A. Portfolio

Follow Axa S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.